IL160060A0 - Piperidine derivatives useful as ccr5 antagonists - Google Patents

Piperidine derivatives useful as ccr5 antagonists

Info

Publication number
IL160060A0
IL160060A0 IL16006002A IL16006002A IL160060A0 IL 160060 A0 IL160060 A0 IL 160060A0 IL 16006002 A IL16006002 A IL 16006002A IL 16006002 A IL16006002 A IL 16006002A IL 160060 A0 IL160060 A0 IL 160060A0
Authority
IL
Israel
Prior art keywords
derivatives useful
piperidine derivatives
ccr5 antagonists
ccr5
antagonists
Prior art date
Application number
IL16006002A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL160060A0 publication Critical patent/IL160060A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16006002A 2001-08-29 2002-08-28 Piperidine derivatives useful as ccr5 antagonists IL160060A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31568301P 2001-08-29 2001-08-29
PCT/US2002/027389 WO2003020716A1 (en) 2001-08-29 2002-08-28 Piperidine derivatives useful as ccr5 antagonists

Publications (1)

Publication Number Publication Date
IL160060A0 true IL160060A0 (en) 2004-06-20

Family

ID=23225580

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16006002A IL160060A0 (en) 2001-08-29 2002-08-28 Piperidine derivatives useful as ccr5 antagonists

Country Status (23)

Country Link
US (4) US20040010008A1 (de)
EP (1) EP1421075B1 (de)
JP (2) JP4223950B2 (de)
KR (1) KR20040029057A (de)
CN (1) CN1304389C (de)
AR (1) AR036366A1 (de)
AT (1) ATE328879T1 (de)
BR (1) BR0212108A (de)
CA (1) CA2457861A1 (de)
CY (1) CY1105198T1 (de)
DE (1) DE60212146T2 (de)
DK (1) DK1421075T3 (de)
EC (1) ECSP044993A (de)
ES (1) ES2264491T3 (de)
HU (1) HUP0402019A3 (de)
IL (1) IL160060A0 (de)
MX (1) MXPA04001886A (de)
NO (1) NO20041266L (de)
PL (1) PL368827A1 (de)
PT (1) PT1421075E (de)
RU (1) RU2004109510A (de)
WO (1) WO2003020716A1 (de)
ZA (1) ZA200401594B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108876D0 (en) * 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
PT1404667E (pt) 2001-07-02 2006-07-31 Astrazeneca Ab Derivados de piperidina uteis como moduladores da actividade do receptor de quimiocina
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
GB0223223D0 (en) * 2002-10-07 2002-11-13 Novartis Ag Organic compounds
AU2003301299A1 (en) 2002-10-15 2004-05-04 Janssen Pharmaceutica, N.V. Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
KR20060100409A (ko) * 2003-11-03 2006-09-20 쉐링 코포레이션 케모킨 수용체 억제제로서 유용한 비피페리디닐 유도체
JP2007513082A (ja) * 2003-11-10 2007-05-24 シエーリング アクチエンゲゼルシャフト Ｃｃｒ−５アンタゴニストとして有用なベンジルエーテルアミン化合物
CN103012374B (zh) 2004-04-13 2015-05-20 因塞特公司 作为趋化因子受体拮抗剂的哌嗪基哌啶衍生物
WO2006071875A1 (en) * 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006071958A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006077499A1 (en) * 2005-01-20 2006-07-27 Pfizer Limited Chemical compounds
MX2007010257A (es) * 2005-02-23 2007-09-11 Schering Corp Derivados de piperidinil piperidina utiles como inhibidores de receptores de quimiocinas.
US20070010565A1 (en) * 2005-04-25 2007-01-11 Olaf Prien New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents
JP2009501793A (ja) 2005-07-21 2009-01-22 アストラゼネカ・アクチエボラーグ 新規ピペリジン誘導体
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
CN101801952A (zh) 2007-10-01 2010-08-11 弗·哈夫曼-拉罗切有限公司 用作ccr受体拮抗剂的n-杂环联芳基甲酰胺类化合物
EP2297137A1 (de) * 2008-06-18 2011-03-23 F. Hoffmann-La Roche AG Neuartige heteroarylcarboxamidderivate
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
WO2015091420A1 (de) * 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituierte bipiperidinyl-derivate als adrenrezeptor alpha 2c antagonisten
US20160318866A1 (en) 2013-12-19 2016-11-03 Bayer Pharma Aktiengesellschaft Substituted bipiperidinyl derivatives
JP2017501164A (ja) 2013-12-19 2017-01-12 バイエル ファーマ アクチエンゲゼルシャフト 置換されたピペリジニルテトラヒドロキノリン類
MX365289B (es) 2013-12-19 2019-05-29 Bayer Pharma AG Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alfa-2c.
US11311552B2 (en) 2015-04-02 2022-04-26 Proximagen, Llc Therapies for cancer
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
MX2024002139A (es) 2021-08-18 2024-03-06 Chemocentryx Inc Arilsulfonil(hidroxi)piperidinas como inhibidores de ccr6.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588722A (en) * 1984-01-09 1986-05-13 Janssen Pharmaceutica N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
TW531537B (en) * 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) * 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
ATE227708T1 (de) * 1996-07-10 2002-11-15 Schering Corp 1,4-disubstituierte piperdine als muskarin- antagonisten
JP3894729B2 (ja) * 1999-05-04 2007-03-22 シェーリング コーポレイション Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体
AU7788500A (en) * 1999-10-25 2001-05-08 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0108876D0 (en) * 2001-04-09 2001-05-30 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
US20040010008A1 (en) 2004-01-15
DE60212146D1 (de) 2006-07-20
CN1551877A (zh) 2004-12-01
DE60212146T2 (de) 2007-06-06
CA2457861A1 (en) 2003-03-13
MXPA04001886A (es) 2004-06-15
US7442703B2 (en) 2008-10-28
RU2004109510A (ru) 2005-10-20
PL368827A1 (en) 2005-04-04
US7384948B2 (en) 2008-06-10
HUP0402019A2 (hu) 2005-02-28
JP2008222722A (ja) 2008-09-25
EP1421075A1 (de) 2004-05-26
JP2005502682A (ja) 2005-01-27
ZA200401594B (en) 2004-11-24
CN1304389C (zh) 2007-03-14
US20040092745A1 (en) 2004-05-13
DK1421075T3 (da) 2006-09-18
PT1421075E (pt) 2006-10-31
US20040092551A1 (en) 2004-05-13
US20080214575A1 (en) 2008-09-04
BR0212108A (pt) 2004-08-24
HK1061563A1 (en) 2004-09-24
ES2264491T3 (es) 2007-01-01
AR036366A1 (es) 2004-09-01
KR20040029057A (ko) 2004-04-03
ATE328879T1 (de) 2006-06-15
NO20041266L (no) 2004-03-26
US8034933B2 (en) 2011-10-11
CY1105198T1 (el) 2010-03-03
HUP0402019A3 (en) 2009-07-28
EP1421075B1 (de) 2006-06-07
JP4223950B2 (ja) 2009-02-12
WO2003020716A1 (en) 2003-03-13
ECSP044993A (es) 2004-04-28

Similar Documents

Publication Publication Date Title
IL160060A0 (en) Piperidine derivatives useful as ccr5 antagonists
IL145742A0 (en) Piperidine derivatives useful as ccr5 antagonists
EG24136A (en) Piperazine derivatives useful as ccr5 antagonists
IL162484A (en) Pyrrolidine and piperidine derivatives as nk1 antagonists
EP1451173A4 (de) Piperidine
PL356034A1 (en) Cyclic amine compounds as ccr5 antagonists
PL375220A1 (en) Piperidine derivatives
IL152209A0 (en) Benzoamide piperidine compounds as substance p antagonists
IL159697A0 (en) Substituted anilinic piperidines as mch selective antagonists
GB0108099D0 (en) Aminopiperidine derivatives
IL160750A0 (en) Quinoline derivatives as neuropeptide y antagonists
IL162765A0 (en) Piperidine derivatives
AU2002366320A1 (en) Lactams as tachykinin antagonists
IL181191A0 (en) Piperazine and piperidine derivatives and their use as chemokine receptor antagonists
IL157713A0 (en) Aryl oxime-piperazines useful as ccr5 antagonists
IL144299A0 (en) N-triazolymethyl-piperazine derivatives as neurokinin receptor antagonists
AU2673201A (en) Alpha-arylethylpiperazine derivatives as neurokinin antagonists
HK1074841A (en) Piperidine derivatives useful as ccr5 antagonists
HK1085118A (en) Piperidine derivatives as ccr5 antagonists
HK1082913A (en) Piperidine derivatives as ccr5 antagonists
SI1421075T1 (sl) Derivati piperidina, koristni kot antagonisti CCR5
GB0104583D0 (en) Piperidine derivatives
AU2002340142A1 (en) Piperidine compounds as muscarinic antagonists
HK1062304A (en) Piperidine compounds as muscarinic antagonists
AU2002251242A1 (en) Piperazine derivatives as tachykinin antagonists